

Preparation, Pharmacokinetics, and Antitumor Potential of Miltefosine-Loaded Nanostructured Lipid Carriers [Retraction]

Yu G, Ali Z, Sajjad Khan A, et al. *Int J Nanomedicine*. 2021;16:3255-3273.

At the authors request, the Editor and Publisher of *International Journal of Nanomedicine* wish to retract the published article. Concerns were raised regarding the alleged duplication of images in Figures 9A, 9B and 9C with the same images from a previous article (ud Din et al, 2017 <https://doi.org/10.1080/10717544.2016.1272651>) by the same authors. Specifically,

- Figure 9A, Untreated Control, Pure Drug, HePC-NLCs, Normal Saline and all corresponding Tumor mass images appear to have been duplicated with the same images for Figure 6A, Control, Solution, DRTN, and Hydrogel images, respectively, from ud Din et al, 2017.
- Figure 9B, Pure Drug, Caspas-3; HePC-NLCs, Caspas-3 and Normal Saline, Caspas-3 appear to have been duplicated with the same images from Figure 6C, Solution, Ki-67 and Figure 6B, DRTN, Caspase-3 and Control, Caspase-3, respectively, from ud Din et al, 2017.
- Figure 9C, Untreated Control, PARP; Pure Drug, PARP; HePC-NLCs, PARP and Normal Saline, PARP appear to have been duplicated with the same images from Figure 6C, Hydrogel, CD31; Figure 6B, Solution, PARP; Figure 6C, Control, CD31 and Figure 6B, Control, PARP, respectively, from ud Din et al, 2017.

The authors responded to our queries and agreed with the concerns that had been raised and requested for the retraction of the article. The Editor agreed with this decision and approved the authors retraction request.

We have been informed in our decision-making by our policy on publishing ethics and integrity and the COPE guidelines on retractions.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.